# DESCRIPTION

## FIELD OF THE INVENTION

- define field of medicine

## BACKGROUND

- introduce activins and their effects
- discuss prior art and need for specific inhibitors

## BRIEF SUMMARY OF THE INVENTION

- introduce method of preventing or treating cardiac dysfunction
- specify Activin A specific antagonist
- describe antibody or antigen-binding fragment
- specify binding characteristics
- describe blocking of Activin A receptor binding
- specify inhibition of SMAD complex signaling
- describe antibody or antigen-binding fragment composition
- specify heavy and light chain variable regions
- describe antibody or antigen-binding fragment with specific sequences
- specify administration with GDF8 antagonist
- describe pharmaceutical composition
- specify use in treating COVID-19

## DETAILED DESCRIPTION

- set scope and definitions

### Methods of Preventing and Treating Cardiac Dysfunction and Heart Failure

- introduce cardiac dysfunction and heart failure
- motivate Activin A specific antagonist treatment
- define prevention and treatment of heart failure
- describe effective amount of Activin A specific antagonists
- define heart failure and its clinical manifestations
- categorize heart failure based on side, function, and degree of illness
- classify heart failure based on functional impairment (NYHA)
- describe ACC staging system for heart failure
- define cardiac remodeling and its triggers
- describe hallmarks of cardiac remodeling
- summarize cardiac dysfunction and heart failure treatment
- introduce cardiac dysfunction and heart failure
- describe Activin A specific antagonists
- motivate treatment of cardiac remodeling
- list disorders leading to heart failure
- define hypertension
- define cardiac arrhythmia
- define cardiac hypertrophy
- explain ejection fraction
- describe heart failure classification
- motivate reducing cardiovascular events
- describe reducing hospitalizations for heart failure
- describe improving survival of heart failure patients
- describe reducing risk of cardiovascular death
- describe treating cardiac dysfunction in COVID-19 patients
- list approved drugs and supportive therapies for heart failure
- describe combination therapy for heart failure
- conclude treatment methods

### Activin A-Specific Antagonists

- introduce Activin A-specific antagonists
- define antigen-specific binding protein
- describe Activin A-specific binding proteins
- specify βA subunit sequence
- specify βB subunit sequence
- describe Activin A, Activin B, Activin AB, and Activin AC
- define Activin A-specific binding protein binding properties
- introduce GDF8-specific binding proteins
- define GDF8-specific binding protein binding properties
- exclude ActRIIB-Fc from binding protein definition
- specify human version of proteins and polypeptides
- define specific binding
- describe methods for determining specific binding
- introduce antibodies and antigen-binding fragments
- describe antibody structure and function
- define antigen-binding fragments
- describe recombinant human antibodies
- define isolated antibody
- define neutralizing antibody
- describe antibody mutations
- describe germline mutations
- describe conservative substitutions
- define epitope
- define substantial identity
- describe sequence similarity
- describe antibody sequence analysis
- describe HCVR sequences
- describe LCVR sequences
- describe HCVR/LCVR sequence pairs
- define activin A-specific antagonists
- specify antibody or antigen-binding portion sequences
- describe non-limiting, exemplary antibodies and antigen-binding fragments
- specify HCVR and/or LCVR sequences
- describe methods for identifying CDRs
- introduce modified carbohydrate content
- describe biological characteristics of antibodies
- specify binding affinity to Activin A
- describe inhibition of Activin A-mediated cellular signaling
- introduce anti-Activin A antibodies comprising Fc variants
- describe Fc modifications for enhanced or diminished binding to FcRn
- specify non-limiting examples of Fc modifications
- describe chimeric heavy chain constant regions
- specify chimeric hinge regions
- describe modified Fc effector functions
- define Activin A-specific antagonists
- epitope mapping techniques
- epitope excision and extraction methods
- hydrogen/deuterium exchange method
- antibody binding assays
- epitope competition assays
- antibody cross-competition assays
- prepare human antibodies
- generate fully human monoclonal antibodies
- characterize and select antibodies
- define bioequivalents
- bioequivalence measures
- species selectivity and cross-reactivity
- multispecific antibodies
- bi-specific antibody formats
- link antibodies to functional molecules
- conjugate antibodies to therapeutic moieties
- formulate pharmaceutical composition
- describe carriers and excipients
- discuss dose and administration
- outline delivery systems
- describe controlled release systems
- discuss injectable preparations
- introduce combination therapies
- list additional therapeutically active components
- describe administration timing
- define concurrent administration
- discuss co-formulation of anti-Activin A antibody with additional components
- provide examples of reusable pen delivery devices
- provide examples of disposable pen delivery devices
- discuss controlled release systems
- outline injectable preparations
- define dosage
- specify dosage amounts
- describe administration regimens
- define sequential administration
- specify dose frequencies
- describe loading and maintenance doses
- introduce kits
- describe kit components

## EXAMPLES

- provide examples of invention

### Example 1. Generation of Human Antibodies to Activin A

- generate human antibodies to Activin A

### Example 2. Heavy and Light Chain Variable Region Amino Acid Sequences

- describe heavy and light chain variable region amino acid sequences

### Control Constructs Used in the Following Examples

- describe control constructs used in following examples

### Example 3. Antibody Binding to Human Activin A as Determined by Surface Plasmon Resonance

- describe surface plasmon resonance assay
- determine kinetic binding parameters
- analyze binding data

### Example 4. Inhibition of Activin A-Mediated Receptor Activation and SMAD Complex Signaling with Anti-Activin A Antibodies

- describe bioassay for activin A-mediated receptor activation
- measure inhibition of activin A-mediated receptor activation
- analyze inhibition data
- test antibodies for blocking activin B, AB, and AC
- analyze blocking data

### Example 5. Blocking of Activin A Binding Using Activin A Antibodies

- describe blocking of activin A binding to receptors and follistatin
- analyze blocking data

### Example 6. Activin A Induces Upstream Signaling and Activates Cardiac Stress Genes in Human Induced Pluripotent Stem Cell Cardiomyocytes

- describe culture of human induced pluripotent stem cell-derived cardiomyocytes
- analyze activin A-induced signaling and gene expression
- analyze inhibitory effect of activin A antibody on signaling and gene expression

### Example 7. Anti-Activin A Induces Contractile and Electrophysiologic Dysfunction of IPSC-Cardiomyocytes that is Blocked by Anti-Activin A Antibodies

- describe experimental setup
- measure contractility and electrophysiology
- analyze impedance and EFP data
- demonstrate prevention of impaired function by anti-Activin A antibody

### Example 8. Serum Levels of Activin A, Follistatin-Related Gene (FLRG) and Plasminogen Activator Inhibitor-1 (PAI-1) are Increased in COVID-19 Patients, and Correlate with Disease Severity

- collect and analyze serum samples
- measure concentrations of Activin A, FLRG, and PAI-1
- report descriptive statistics
- perform Kruskal Wallis tests and Wilcoxon signed-rank tests
- analyze longitudinal outcomes
- demonstrate correlation with disease severity
- summarize laboratory results and clinical outcomes

